Skip to content

Back-to-back US FDA approvals boost Zydus Lifesciences; stock at 8-month high

The US accounts for 40 percent of the company’s revenue, which is why each FDA approval is a positive

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish